Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
104.63
-1.03 (-0.97%)
At close: Nov 26, 2025, 4:00 PM EST
104.63
0.00 (0.00%)
After-hours: Nov 26, 2025, 6:30 PM EST
Merck & Co. Employees
As of December 31, 2024, Merck & Co. had 75,000 total employees, including 73,000 full-time and 2,000 part-time employees. The number of employees increased by 3,000 or 4.17% compared to the previous year.
Employees
75,000
Change (1Y)
3,000
Growth (1Y)
4.17%
Revenue / Employee
$856,467
Profits / Employee
$253,787
Market Cap
259.69B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 75,000 | 3,000 | 4.17% |
| Dec 31, 2023 | 72,000 | 3,000 | 4.35% |
| Dec 31, 2022 | 69,000 | 1,000 | 1.47% |
| Dec 31, 2021 | 68,000 | -6,000 | -8.11% |
| Dec 31, 2020 | 74,000 | 3,000 | 4.23% |
| Dec 31, 2019 | 71,000 | 2,000 | 2.90% |
| Dec 31, 2018 | 69,000 | 0 | - |
| Dec 31, 2017 | 69,000 | 1,000 | 1.47% |
| Dec 31, 2016 | 68,000 | 0 | - |
| Dec 31, 2015 | 68,000 | -2,000 | -2.86% |
| Dec 31, 2014 | 70,000 | -6,000 | -7.89% |
| Dec 31, 2013 | 76,000 | -7,000 | -8.43% |
| Dec 31, 2012 | 83,000 | -3,000 | -3.49% |
| Dec 31, 2011 | 86,000 | -8,000 | -8.51% |
| Dec 31, 2010 | 94,000 | -6,000 | -6.00% |
| Dec 31, 2009 | 100,000 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| AbbVie | 55,000 |
MRK News
- 10 hours ago - Why Is Merck Stock Surging? - Forbes
- 11 hours ago - Merck to Participate in the Citi 2025 Global Healthcare Conference - Business Wire
- 12 hours ago - Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference - Business Wire
- 2 days ago - Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches - Business Wire
- 3 days ago - Steven Cress' 6 Picks: 3 Dividend Income, 3 AI Growth Stocks - Seeking Alpha
- 4 days ago - Merck Recommends Rejection of Tutanota's “Mini-Tender” Offer - Business Wire
- 5 days ago - FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer - Business Wire
- 5 days ago - Retirement: 2 Healthcare Giants To Buy At Discounted Prices - Seeking Alpha